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Poster Session I S295cell infiltration. In contrast, no WT1 expression was observed when
disease was absent.
Our findings suggest an association between the emergence of
WT1-specific T cells and graft-versus-myeloma effect in pts being
treated for relapsed MM.246
UPFRONT TANDEM AUTOLOGOUS STEM CELL TRANSPLANT IS SUPERIOR
THAN AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANT AFTER
FAILURE OF 1ST AUTOLOGOUS TRANSPLANT IN PATIENTS WITH MULTI-
PLE MYELOMA
Bachier, C., Wong, A., Shaughnessy, P., LeMaistre, C.F. Texas Trans-
plant Institute, San Antonio, TX
Disease progression remains the main cause of treatment failure
after autologous stem cell transplant (SCT) in patients with multiple
myeloma (MM). It is unclear what is the best salvage therapy after
failure of a 1st autologous SCT in MM.
We performed a retrospective study comparing 2nd autologous
(auto-auto) versus 2nd allogeneic (auto-allo) SCT in patients pro-
gressing or relapsing after their 1st autologous SCT and compare
their outcomes with patients receiving sequential planned double au-
tologous (tandem) SCT as part of their upfront therapy for MM.
The data was collected from CIBMTR reports and medical re-
cords at Texas Transplant Institute from 2001 to 2010. Patient’s
characteristics and outcomes are described in table. Response to 1st
and 2nd SCT was determined at 100 days post transplant and classi-
fied as good (stringent complete remission [sCR], complete remis-
sion [CR], very good partial remission [VGPR]) or poor (partial
remission [PR], stable disease [SD] or progressive disease [PD]).
All patients in the auto-allo group received a reduced intensity reg-
imen. The overall survival was calculated from the date of the 2nd
transplant to the known date of death in all groups. Patients in the
auto-allo group (15.9 months) had a worse median survival than in
the auto-auto group (39 months) with both of them having a worse
survival compared to patients undergoing tandem transplants
(64.3) (p value 5 0.003).
Forward stepwiseCox regression analysis was used tomeasure fac-
tors affecting overall survival. Factors used for analysis included age,
cytogenetics (high risk 5 mutated p53, t(14;16), t(4;14), del 13), In-
ternational Staging System (ISS) before 1st and 2nd SCT, use of
maintenance therapy after 1st SCT, days from diagnosis to 1st SCT
and days from 1st to 2nd SCT, CD34+ cells infused at 1st and 2nd
SCT. Age and ISS of III at 2nd transplant were identified as factors
affecting survival in the auto-auto group (hazard ration of 1.081
and 5.700, respectively).Table. Patient Characteristics and Outcomes
Tandem (n 5 29)
Median age, years (range) 62 (41-78)
Median days from diagnosis to 1st transplant 224.5 (93-1344)
Median days from 1st to 2nd transplant 149 (99-189)
Median total CD34+ cell infused 1st transplant 3.29 (2-12)
Median total CD34+ cell infused 2nd transplant 3.22 (2-9)
Median WBC engraftment 11 (9-13)
Median Platelet engraftment 16 (10-19)
Cytogenetics-High Risk 17%
ISS at 1st transplant I 31%
ISS at 1st transplant II 34%
ISS at 1st transplant III 14%
ISS at 2nd transplant I 48%
ISS at 2nd transplant II 17%
ISS at 2nd transplant III 10%
Response to 1st transplant Good 10%
Response to 1st transplant Poor 80%
Response to 2nd transplant Good 52%
Response to 2nd transplant Poor 80%
Median Followup (months) 57.1 (3.4-76.7)In conclusion, overall survival after salvage from 2nd autologous
stem cell transplant is longer than after a 2nd allogeneic transplant.
Upfront, planned tandem autologous stem cell transplant is superior
to both salvage strategies. Larger, randomized trials are needed to
confirm these results.247
RETROSPECTIVE REVIEW OF DPACE THERAPY AS A SALVAGE REGIMEN
IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA PRIOR TO AUTOLO-
GOUS STEM CELL TRANSPLANT
Snider, J.N.1, Stelts, S.D.2, Awan,M.3, Raza,M.3, Goorha, S.3 1Univer-
sity of Tennessee Health Sciences Center, Memphis, TN; 2Methodist
University Hospital, Memphis, TN; 3Boston Baskin Cancer Foundation,
Germantown, TN
Background: The landscape of multiple myeloma (MM) treatment
has improved substantially since the introduction of novel agents
thalidomide, bortezomib and lenolidomide. However, it is not al-
ways clear what therapy would be effective in patients after they
progress with these novel agents. To identify effective salvage ther-
apy, we performed a retrospective review of DPACE (dexametha-
sone, cisplatin, doxorubicin, cyclophosphamide, and etoposide)
chemotherapy in pretreated MM patients who were candidates for
autologous stem cell transplant (ASCT).
Methods: Review of electronic medical records at our institution
from January 1, 2005 to July 31, 2011 was performed. Eligible sub-
jects were $18 years old with a diagnosis of MM that received
DPACE after their disease had progressed with chemotherapy in-
cluding a novel agent and were transplant candidates. Data collected
included ISS stage at diagnosis, response to therapy, safety data, time
to transplant, and time to progression and death.
Results:We evaluated 24 patients who had received a median num-
ber of 2 (range 1-4) prior therapies, excluding single agent dexame-
thasone.Prior to DPACE, 38% (n 5 9) had undergone at least one
ASCT. The median number of DPACE cycles was 2 (range 1-5).
Median age was 57 (range 46 - 75); 75 % (n 5 18) were African-
American and 25% (n 5 6) were Caucasian. Partial response or
greater was achieved in 79% (n 5 19), stable disease in 13% (n 5
3), and 8% had progressive disease (n5 2). Dose reduction occurred
in 25% (n 5 6) of patients with dose reductions ranging from 20 to
50%. Sixteen patients (67%) proceeded to ASCT including five of
the 9 (55%) who had prior ASCT. Median time to transplant was
3 months (range 2 -11) from first DPACE cycle. Six patients experi-
enced CTCAE v4.0 grade 3/4 neutropenia with only 16% (n5 4) fe-
brile neutropenia. All patients received growth factor support. Grade
3/4 thrombocytopenia (n5 2), anemia (n5 2), and mucositis (n5 2)Auto-Auto (n 5 32) Auto-Allo (n 5 10)
62.5 (45-81) 54 (43-63)
226 (117-1074) 254.5 (101-416)
847 (210-4158) 350 (88-1281)
5.87 (2-28) 6.03 (2-14)
4.47 (2-19) 5.25 (3-11)
11 (9-47) N/A
15 (10-23) N/A
3% 10%
41% 40%
12% 0
6% 10%
53% 40%
9% 0
13% 10%
63% 70%
25% 20%
47% 30%
25% 20%
24.6 (10.5-87.8) 48.0 (31.9-64.0)
S296 Poster Session Iwhere the next most common toxicities. Solitary cases of cardiotox-
icity, renal dysfunction, and orthostatic hypotension were observed.
Conclusion: Based on this small cohort of relapsed, transplant
eligible MM patients, DPACE appears to be safe and effective
salvage therapy that may serve as a bridge to ASCT. Ongoing
work is being performed to compare the effectiveness of this reg-
imen with other salvage therapies used in a similar population of
MM patients and to measure progression free and overall survival
after treatment.248
BI-MODAL AGE DISTRIBUTION OF PATIENTS WITH RELAPSED HODGKIN
LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTA-
TION CORRELATES WITH MARKEDLY INFERIOR SURVIVAL AMONG PA-
TIENTS AGE 35 YEARS AND OLDER
Sharma, A.1, Duan, M.2, Chowdhury, R.5, Graiser, M.3, Zhang, H.1,
Langston, A.1, Lonial, S.1, Flowers, C.R.1, Haight, A.4, Waller, E.K.1
1Winship Cancer Institute, Emory University School of Medicine, Atlanta,
GA; 2Emory University Hospital, Atlanta, GA; 3Emory University, At-
lanta, GA; 4Children’s Healthcare of Atlanta, Atlanta, GA; 5James T.
Laney Graduate School, Emory University, Atlanta, GA
Background: About 1/3 of advanced Hodgkin lymphoma (HL) pa-
tients fail first line therapy and are candidates for autologous stem
cell transplantation (ASCT). Surveillance, Epidemiology and End
Results (SEER) data indicates a bi-modal age distribution and supe-
rior survival among children/adolescents with HL (Bazzeh 2010).
The aim of this study was to analyze the impact of age on overall sur-
vival (OS) among patients with relapsed/refractory HL undergoing
ASCT. We hypothesized that 1) HL patients undergoing ASCT
have a bi-modal age distribution; 2) the older age cohort has inferior
OS after ASCT.
Patients andMethods:We performed an IRB approved, retrospec-
tive analysis of a combined cohort of 131 adult and pediatric HL pa-
tients undergoing ASCT at Emory University from 1995 to 2011.
The cohort included 54% male, 65% Caucasians, and 26% African
American patients. OS was compared using Kaplan Meier estimates
for the time-to-event analysis and log rank test. Univariate and mul-
tivariate Cox proportional hazards models were used to test our hy-
potheses.
Results: Hypothesis 1: Two age cohorts of HSCT patients were
identified: younger (#35 years, n 5 96) and older (.35 years old,
n5 35), based on a bimodal distribution similar to SEER incidence.
Hypothesis 2: Univariate analysis showed a significantly higher post-
transplant mortality (p5 0.004) for patients.35 compared to those
#35 years. Multivariate analysis, adjusting for gender, race, histol-
ogy, disease status at transplant and stage, showed a hazard ratio of
2.4 for patients.35 years compared to those#35 years of age. His-
tology was similar across the age groups, with 75% patients having
nodular sclerosing histology.
Conclusions:Our analysis showsmarkedly inferiorOS among older
patients with undergoing ASCT.The age related differences in post-
transplant survival were not explained by the decreased actuarial life
expectancy of older subjects based upon life-table projections of sur-
vival for the general population.While there were differences in sup-
portive care, toxicity from treatments, and co-morbid diseases
among older HL patients undergoing ASCT compared with youn-
ger HL patients, the inferior survival of older HL patients undergo-
ing ASCT suggests that theremay be differences in the biology of the
disease based upon the age at which HL is diagnosed. Alternative
strategies for autologous transplantation of older patients with re-
lapsed/refractory HL are needed.249
EPIGENETIC CHANGES ENHANCE THE CYTOTOXICITY OF COMBINED
NUCLEOSIDE ANALOG-DNA ALKYLATING AGENTS IN LYMPHOMA CELLS
Valdez, B.C.1, Nieto, Y.1, Murray, D.2, Li, Y.1, Wang, G.1,
Champlin, R.E.1, Andersson, B.S.1 1UT MD Anderson Cancer Center,
Houston, TX; 2Cross Cancer Institute, Edmonton, AB, CanadaLymphomas are heterogeneous diseases that require combination
therapy for an effective control. A sizable fraction of patients still fail
to respond, or suffer progressive disease, after initially responding to
treatment. In this setting, hematopoietic stem cell transplantation
(HSCT) has been effective particularly in patients who respond to
salvage chemotherapy. In an attempt to design more efficacious
and safe pre-HSCT conditioning treatment, we expanded our
previous observation on the synergistic cytotoxicity of nucleoside-
analog-(NA) andDNA alkylating agent (AA) and investigated the in-
teractions between AAs busulfan (Bu) and melphalan (Mel) and NA
gemcitabine (Gem) in human lymphoma cell line J45.01. We used
IC10 drug concentrations (57 mM Bu, 1 mM Mel and 0.02 mM
Gem) which individually did not have significant effects on cell pro-
liferation. However, their combination resulted in 50% inhibition of
proliferation. Reduction to almost half (20 mM Bu, 0.7 mMMel and
0.01 mM Gem) did not result in inhibition of cell proliferation. Ad-
dition of 0.6 mM suberoylanilide hydroxamic acid (SAHA) to the lat-
ter combination resulted in 65% inhibition of proliferation. The
synergistic cytotoxicity of [Bu+Mel+Gem+SAHA] combinations
correlates with the activation of the ATM-CHK2 pathway, phos-
phorylaton of KAP1, epigenetic changes such as methylation and
acetylation of histone 3, and activation of apoptosis. We deduce
that chromatin alterations mediated by Gem and SAHA may make
genomic DNAmore accessible to DNA alkylation by Bu andMel re-
sulting in increased DNA lesions and commitment of cells to apo-
ptosis. The relevance of epigenetic changes in this drug exposure is
further shown by the induction of expression of DNA methyltrans-
ferases in lymphoma (and leukemia) cells, which have low constitu-
tive levels of DNMT3A and DNMT3B proteins. The addition of
5-aza-2’-deoxycytidine (DAC) to [Bu+Mel+Gem+SAHA] further
enhances cell killing.Our results suggest that epigenetic changesme-
diated by Gem, SAHA and DAC alter chromatin structure and en-
hance DNA alkylation with Bu and Mel. Such effects are further
aggravated by the ability of Gem to inhibit ribonucleotide reductase
andDNA repair. In summary, this study expands our previous obser-
vation of NA-mediated synergistic toxicity mediated by AAs, and
provides a basis to justify future mechanism-based clinical trials us-
ing [Bu+Mel+Gem+SAHA] as pre-HSCT conditioning for patients
with chemotherapy-refractory lymphoma.250
IMPROVED OUTCOME OF AFRICAN AMERICAN MULTIPLE MYELOMA PA-
TIENTS WITH NOVEL AGENTS AND AUTOLOGOUS STEM CELL TRANS-
PLANT
Saraf, S., Patel, P., Ozer, H., Peace, D., Quigley, J., Mahmud, N.,
Rondelli, D. University of Illinois Medical Center, Chicago, IL
African Americans (AA) have twice the risk of developing mul-
tiple myeloma (MM) and, in prior studies, a higher mortality rate
when compared to non-African Americans (non-AA). Novel
agents, such as thalidomide, lenalidomide and bortezomib have
improved the outcome of MM patients but the impact of these
new therapies in AA patients has not been evaluated. In this
study, 53 consecutive patients (23 AA, 30 non-AA) with newly di-
agnosed MM were retrospectively analyzed after induction treat-
ment incorporating a novel agent. AA and non-AA patients were
comparable for age, immunoglobulin isotype, stage of disease, se-
rum albumin level, and cytogenetic abnormalities including del13
(27% vs. 38%, respectively, p 5 NS). Median serum level of a^2
microglobulin at diagnosis was higher in AA than non-AA (5.9
mg/L vs. 3.5 mg/L, p 5 0.024). Using the international uniform
criteria, response rates to induction therapy were not statistically
different between AA and non-AA: overall response rate (ORR,
91% vs. 77%), complete remission (CR, 22% vs. 27%), very
good partial remission (VGPR, 26% vs. 20%), or partial remis-
sion (PR, 43% vs. 30%). However, rate of progressive disease
was significantly higher in non-AA patients (p 5 0.03). Of 53 pa-
tients, 46 (20 AA, 26 non-AA) received standard high-dose che-
motherapy followed by autologous stem cell transplant (ASCT).
With a median follow-up of 47 months, the ORR to ASCT
was 89% in AA and 85% in non-AA, CR+VGPR rates were
61% in AA and 45% in non-AA (p 5 NS). Disease-free survival
